NEW THIAZOLIDINE DERIVATIVES, PROCESS FOR PREPARING SAME AND ANTI-AMNESTIC COMPOSITION CONTAINING SAME

Abstract: New thiazolidine derivatives of the general formula I wherein X stands for a proline or thioproline residue and R for -CH₂OH or -CHO, a process for preparing same which comprises reacting N-benzyloxycarbonyl-L-proline or -L-thioproline with L-­ thioprolinol and, optionally, oxidizing the resultant N-­ benzyloxycarbonyl-L-prolyl-L-thioprolinol or -L-thioprolyl-L-­ thioprolinol to the corresponding thioprolinal compound, and an anti-amnestic composition containing at least one of the thiazolidine derivatives together with a conventional excipient. The new thiazolidine derivatives are extremely strong in anti-­ amnestic activity as compared with known similar anti-amnestic agents.

Description: The present invention relates to new thiazolidine derivatives possessing very strong anti-amnestic activity, a process for preparing same and an anti-amnestic composition containing at least one of the thiazolidine derivatives together with a conventional excipient. More particularly, the present invention relates to 3-(N-benzyloxycarbonyl)-thioprolyl-4-formyl or hydroxymethyl-thiazolidine, a process for preparing same by reacting 4-benzyloxycarbonyl-thioproline with thioprolinol and, optionally, oxidizing the resultant 4-hydroxymethyl-thiazolidine compound to the corresponding 4-formyl-thiazolidine compound, and an anti-amnestic composition containing the thiazolidine compound together with a conventional excipient. As 4-hydroxymethyl and 4-formyl thiazolidines are derived from proline by reduction and are called thioprolinol and thioprolinal, respectively, the nomenclatures of prolinol and prolinal will be used hereinafter for mentioning the compound names concretely in place of the corresponding thiazolidine compounds. However, the compounds of this invention are generally designated herein as the thiazolidine derivatives. In recent years, some prolinal derivatives are reported as having an inhibitory activity to a physiological role of an enzyme in neuropeptide metabolism. For example, T.C. Friedman et al. reported in J. Neurochem. 42 , 237(1984) that N-benzyloxycarbonyl-L-prolyl-L-prolinal (Z-pro-prolinal) exhibited in vivo an inhibitory activity to prolyl endopeptidase. In M. Nanri et al., Folia Pharmacol. japon, 89 , 323-329(1987) and K. Taira et al., ibid. 89 , 243-252, there is described that some prolinal derivatives exhibit an inhibitory activity to prolyl endopeptidase in experiments using mice as test animal and the use of these derivatives has possibility for the remedy of senile dementia. A similar report is seen in T. Yoshimoto et al., J. Pharmaco bio-Dyn., 10 , 730-735(1987). Further, Japanese Laid-open Patent Appln. No. Sho. 60-172929 discloses that Z-glycyl-L-prolyl-chloromethane or -diazomethane has an inhibitory activity to prolyl endopeptidase and is utilizable as anti-amnestic agent. In JP-A-60-188317, there is disclosed that a prolinal which is N-substituted by an amino acid has an inhibitory activity to prolyl endopeptidase and can thus be used as anti-amnestic agent. Furthermore, JP-A-62-270557 discloses a new process for preparing Z-proprolinal. However, the inhibitory activity to prolyl endopeptidase of these prolinal derivatives is still unsatisfactory in practical level, and so there is a great demand to develop new compounds which exhibit a very strong inhibitory activity to prolyl endopeptidase. EP-A-0 154 353 discloses anti-amnestic agents which comprise as an active ingredient thereof special prolinal derivatives. These derivatives show an inhibitory activity for prolyl endopeptidase and could therefore be useful as anti-amnestic agents. However, neither thioprolinal nor thioprolinol derivatives are mentioned. Special thiazolidine compounds are also mentioned in EP-A-0 303 434 and in EP-A-0 321 956. None of the compounds mentioned in these patent applications include thioprolinal or thioprolinol groups. Accordingly, it is an object of the present invention to provide new thiazolidine derivatives possessing a strong valuable pharmacological property. It is another object of the present invention to provide a process for the preparation of the new thiazolidine derivatives according to a series of methods known per se. It is still another object of the present invention to provide a new type anti-amnestic composition comprised of at least one of the new thiazolidine derivatives. As a result of extensive research made by the present inventors for developing a new anti-amnestic agent, it has now been found that a new class of thiazolidine derivatives which are characterized by containing in their molecule thioprolinol or thioprolinal and a thioprolyl group in a tandem structure exhibit an extremely strong anti-amnestic activity as compared with known similar anti-amnestic compounds. The present invention has been accomplished on the basis of the above finding. In accordance with one embodiment of the present invention, there are provided new thiazolidine derivatives of the general formula I wherein X stands for a thioproline residue and R for -CH₂OH or -CHO. In accordance with another embodiment of the present invention, there is provided a process for the preparation of new thiazolidine derivatives of the general formula I wherein X stands for a thioproline residue and R for -CH₂OH or -CHO, which comprises reacting N-benzyloxycarbonyl -L-thioproline with L-thioprolinol and, optionally, oxidizing the resultant N-benzyloxycarbonyl -L-thioprolyl-L-thioprolinol with an oxidizing agent to N-benzyloxycarbonyl -L-thioprolyl-L-thioprolinal. In accordance with still another embodiment of the present invention, there is provided an anti-amnestic composition which comprises as an active ingredient thereof at least one thiazolidine derivative of the general formula I wherein X stands for a thioproline residue and R for -CH₂OH or -CHO, in a pharmacologically active amount together with a conventional excipient. The new thiazolidine derivatives of the above general formula are prepared in a manner known per se, for example, by reacting N-benzyloxycarbonyl -L-thioproline with L-thioprolinol to form a compound of the general formula wherein R is the grouping -CH₂OH, and, optionally, oxidizing this compound with an oxidizing agent to form a compound of the general formula wherein R is the grouping -CHO. N-Benzyloxy -L-thioproline and L-thioprolinol used in the process of this invention as starting materials are known or can be prepared in a manner known per se. For example, N-benzyloxycarbonyl -L-thioproline can be prepared by acylating L-thioproline with benzyl chlorocarbonate. L-Thioprolinol is commercially available but may be prepared by reducing L-thioproline with a carbonyl-reducing agent such as sodium borohydride or lithium aluminum hydride in a manner known per se. The reaction between N-benzyloxycarbonyl -L-thioproline with L-thioprolinol is carried out normally in a proper solvent such as methylene chloride or chloroform in the presence of 1,3-dimethyl-2-chloroimidazolinium chloride and a tertiary amine such as triethylamine. The resultant N-benzyloxycarbonyl. -L-thioprolyl-L-thioprolinol can be purified by recrystallization from a solvent such as ether. The alcohol moiety, -CH₂OH, of the resultant N-benzyloxycarbonyl -L-thioprolyl-L-thioprolinol can be oxidized, optionally with an oxidizing agent to the corresponding thioprolinal compound having the group -CHO in place of -CH₂OH. As the oxidizing agent in this case, phosgen is used under cooling in the presence of dimethylsulfoxide and a tertiary amine such as triethylamine. The resultant N-benzyloxycarbonyl -L-thioprolyl-L-thioprolinal can be purified by column chromatography on silica gel using chloroform-methanol (50:1) as eluent. The end product of this invention may be prepared in another way; for example, by performing the same reaction as above but starting with a thioproline having an N-protecting acyl group, e.g. N-tert-butyloxycarbonyl-L-thioproline and finally saponifying the N-acyl group in the resultant N-acyl -L-thioprolyl-L-thioprolinol with an alkali and acylating the saponified compound with a benzyloxycarbonyl halide in the presence of a base. The new thiazolidine derivatives of the present invention are extremely strong in anti-amnestic activity as compared with similar known anti-amnestic agents as will be evident from comparative tests given hereinafter. Thus, the thiazolidine derivatives of the present invention can be used for a strong anti-amnestic agent. Accordingly, the present invention is also concerned with an anti-amnestic composition containing at least one of the thiazolidine derivative or derivatives in a pharmacologically active amount together with a conventional excipient. The present invention is further concerned with the use of the anti-amnestic composition for the remedy of memory disorder of human, for example, dementia senilis of Alzheimer's type. The thiazolidine derivatives of the general formula wherein R is the grouping -CHO (thioprolinal derivatives) are very strong in the inhibitory activity and so are as such useful as medicaments for the remedy of memory disorder. However, the thiazolidine derivatives of the general formula wherein R is the grouping -CH₂OH (thioprolinol derivatives) are not strong in vitro in the inhibitory activity. Thus, these thiazolidine derivatives (thioprolinol derivatives) can be regarded as useful intermediate products for the preparation of the derivatives of the general formula wherein R is the grouping -CHO (thioprolinal derivatives). However, these thioprolinol derivatives are converted in vivo into the thioprolinal derivatives having strong anti-amnestic effect. The thiazolidine derivatives of the present invention can be administered to patients in various ways such as injection, for example, intravenous, subcutaneous or intramuscular injection and chewable, water-dispersible or drinkable preparations suitable for oral administration. In general, the thiazolidine derivatives are used singly or may be used as a mixture of at least two. On administration to patients, the thiazolidine derivatives are normally blended with a suitable excipient usually employed for pharmaceutical formulations. An excipient utilizable for this purpose includes one or more organic and inorganic substances which are suitable for enteral or parenteral administration and do not react with the thiazolidine derivatives of the general formula, for example, water, vegetable oils, benzyl alcohol, polyethylene glycols, gelatin, carbohydrates such as lactose and starch, magnesium stearate, talc or white petroleum jelly. Other organic and inorganic substances usually employed for preparing various medicaments can also be used as the excipient unless they do not influence the effect of the prolinal derivatives. The formulations used for oral administration must easily be absorbed in digestive organs and are, in particular, powders, tablets, pills, dragees, hard and soft capsules, syrups, juices, drops, elixirs and other orally acceptable liquid preparations, preferably oily or aqueous solutions, suspensions and emulsions. The formulations for various types of injection preparations are as a rule in the form of the above liquid preparations. For injection, the thiazolidine derivatives may be lyophilized and the resulting lyophilizate may be used at need for such injection preparations. The indicated formulations can be sterilized and/or contain one or more auxiliary substances such as lubricants, preservatives, stabilizers and/or wetting agents. emulsifiers, salts for influencing the osmotic pressure, buffer substances, dyestuffs, flavoring agents and/or aroma substances. They can also contain, if desired, one or more further active compounds for example, lecithin, one or more vitamins, and depressants. Particularly preferable as a mode of administration of the thiazolidine derivatives are oral administration and intravenous injection. The daily dose of the thiazolidine derivatives is preferably between 1 mg and 900 mg/kg, especially between 5 mg and 500 mg/kg of body weight in case of oral administration and between 0.5 mg and 500 mg/kg, especially between 1 mg and 200 mg/kg of body weight in case of intravenous injection. The particular dose for each specific patient depends, however, on very diverse factors, for example, the effectiveness of the particular thiazolidine derivative employed, the age, the body weight, the general state of health and the sex, the diet, the time and mode of administration, the rate of elimination, the combination of medicaments and the severity of the particular ailment to which the remedy applies. In the anti-amnestic composition of the present invention, the thiazolidine derivative or derivatives as active ingredient are contained generally in a concentration of 0.1% or more, preferably 1-50% by weight. Described below are the inhibitory action of the thiazolidine derivatives of the present invention to prolyl endopeptidase and the anti-amnestic effect of the thiazolidine derivatives on rats according to a step-down type passive avoidance test. (1) Inhibitory activity of the thiazolidine derivatives to prolyl endopeptidase in terms of 50% inhibitory concentration (IC₅₀) The inhibitory activity of the thiazolidine derivatives of the present invention is shown below in terms of 50% inhibitory concentration (IC₅₀) in comparison with the known conventional anti-amnestic agent. Inhibitory activity to prolyl endopeptidase Compound IC₅₀ N-Benzyloxycarbonyl-L-prolyl-L-prolinal (control) 0.74 N-Benzyloxycarbonyl-L-thioprolyl-L-thioprolinal(Example 4) 0.0013 N-Benzyloxycarbonyl-L-thioprolyl-L-thioprolinol (Example 3) 600000 In view of the tabulated result, it is noted that N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinal (Example 4) of the present invention is about 600 times as high in inhibitory activity as N-benzyloxycarbonyl-L-prolyl-L-prolinal used as control. N-Benzyloxycarbonyl-L-thioprolyl-L-thioprolinol (Example 3) of the present invention is not effective in vitro but this compound as an intermediate compound of N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinal (Example 4) is oxidized in vivo to an aldehyde form, i.e. the compound of Example 4, exhibiting a satisfactory inhibitory effect. (2) A step-down type passive avoidance test This test was carried out by using the undermentioned apparatus (A) and test animal (B) according to the undermentioned testing method (C). (A) Test chamber for passive avoidance response of rats A test chamber of 200(w) x 200(l) mm in area was made of transparent acrylic resin plates for observation of the inside and was provided on one side thereof with an electrically insulated platform of 150(w) x 200(l) x 40(h) in size and on the bottom with a grid floor made of stainless steel which was equipped with a foot-shock generator/scrumbler (HASG-101/S, Medical Agent, Inc.) capable of sending electric current to the grid floor for giving a test animal electric foot shock. (B) Test animal 5-Weeks-old male rats of Wister strain weighing 100-145 g (Japan Clea Co., Ltd.) were used as test animals. (C) Testing method The passive avoidance test consists of the two steps; an acquisition trial and a retention trial. The thiazolidine derivative of the present invention was dissolved in saline and intraperitoneally administered to the rats in a dose of 2.2 mg/kg body weight one hour before the acquisition trial. As control, only saline was administered intraperitoneally to a group of the rats. In the acquisition trial, the rat was placed on the platform in the test chamber and, when the rat stepped down on the floor, the electric current of 4 mA was immediately sent to the grid continuously until the rat went up on the platform. At the time the rat having gone up on the platform stayed there for more than 20 seconds, the rat was regarded to have learned the situation and taken out of the test chamber. Repeating this test with another rat under the same condition, the rats learned the situation were collected as passing the test for the acquisition trial. A total time of measurement in the acquisition trial was limited to 300 seconds as maximum, and the time elapsing until the rat stepped down to the grid floor (step-down latency, SDL) the total time elapsing until the rat learned the situation and the times of step-down were measured. In order to avoid any significant difference in the rats, those required more than 300 seconds for the first step-down to the grid floor, those stepped down to the floor at least 5 times and those failed to learn the situation within 300 seconds were excluded. Immediately after the acquisition trial, scopolamine hydrobromide (SCOP) dissolved in saline was administered intraperitoneally in a dose of 3.0 mg/kg of body weight to the rat to prepare a SCOP-induced amnestic rat. As control, only saline was administered intraperitoneally to a group of the rats. The retention trial was carried out by putting the rat on the platform of the test chamber after the lapse of 24 and 48 hours from the acquisition trial, and the time elapsing until the rat went down to the floor (SDL) was measured. A statistical treatment of the data obtained was made according to the Student's t-test. A result of the test is shown in the table below. The present invention will now be illustrated by way of Examples wherein DMC and DMSO are abbreviations of 1,3-dimethyl-2-chloroimidazolinium chloride and dimetryl sulfoxide, respectively, and the percentage is by weight unless otherwise indicated. Example 1 Preparation of L-thioprolinol In 900 ml of anhydrous ethanol was suspended 33.8 g of CaCl₂ and the suspension was cooled below -25°C. To this suspension kept below -25°C was added dropwise in 60 minutes under agitation 1400 ml of an ethanolic solution of 11.9 g of NaBH₄. After stirring the mixture for 20 minutes, 300 ml of an ethanolic solution of 60 g of L-thioproline ethyl ester kept below -25°C was added dropwise to the mixture under agitation and the admixture was stirred overnight below -20°C. At room temperature, 60 ml of HCl was added in small portions to the mixture and the whole was concentrated under reduced pressure until dryness. The residue was taken up with an appropriate amount of water and the aqueous solution was washed with chloroform. The solution was then treated with NaHCO₃ to adjust the pH value to 8 and then filtered. The filtrate was extracted 20 times in total with a total amount of 1000 ml of chloroform. The chloroform extracts except those up to 3 times were collected, dried with MgSO₄ and filtered. The filtrate was concentrated under reduced pressure and the product was precipitated twice with hexane and then dried under reduced pressure. Yield: 22 g (59.6%). Example 3 Preparation of N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinol (1) Preparation of N-benzyloxycarbonyl-L-thioproline In 94 ml of 2-N NaOH was dissolved 25 g of L-thioproline, and 20 ml of ether was added to the solution under agitation and ice-cooling. To this solution under agitation were added dropwise 38 ml of benzyloxycarbonyl chloride and 70 ml of 4-N NaOH at the same time in 30 minutes. The mixture was stirred for 2 hours at room temperature, washed with 100 ml of ether and treated with 6-N HCl to adjust pH to 2. The mixture was extracted with 200 ml and 100 ml of ethyl acetate and the ethyl acetate phase was washed 50 ml of water, dried over MgSO₄ and filtered. The filtrate was concentrated until dryness under reduced pressure whereby an oily substance was obtained. Yield: 51 g (100%). (2) Preparation of N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinol In 700 ml of methylene chloride were dissolved with stirring at room temperature 29 g of the oily substance obtained in (1), 45 ml of triethylamine and 12.9 g of L-thioprolinol obtained in Example 1. To this solution was added dropwise in one hour 30 g of DMC in 330 ml of methylene chloride. The mixture was stirred for one hour at room temperature and washed successively with water, a saturated aqueous solution of sodium hydrogen carbonate, 1-N HCl and water. The methylene chloride phase was dried over MgSO₄ and filtered. The filtrate was concentrated until dryness under reduced pressure and the residue was crystallized from ether whereby the end product was obtained. m.p.: 127°C, Yield: 34 g (85.2%). Example 4 Preparation of N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinal To 150 ml of methylene chloride was added at -60°C under agitation 7.5 ml of phosgen in nitrogen atmosphere. To this mixture was then added dropwise in 60 minutes under agitation 150 ml of methylene chloride solution of DMSO 6.2 ml. After stirring the mixture continuously for 5 minutes, 16 g of N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinol obtained in Example 3 in 200 ml of methylene chloride was added dropwise in 40 minutes to the mixture under agitation, and the mixture was then stirred for further 30 minutes. To the mixture was added dropwise 55 ml of triethylamine, and the mixture was stirred until the temperature of the mixture became room temperature. After washing the mixture twice with water, the mixture was dried over MgSO₄ and filtered. The filtrate was concentrated until dryness under reduced pressure, and the residue was subjected to column chromatography on silica gel, using chloroform-methanol (50:1) as solvent. The eluent was concentrated under reduced pressure until dryness. To the residue were added 41 ml of ethanol, 48 g of sodium hydrogen sulfate and 84 ml of water and the mixture was stirred for 15 minutes. The ethanol was removed by distillation and the residual liquid was washed with ether. The aqueous phase was treated with an aqueous solution of potassium carbonate to adjust the pH to 9, and the mixture was extracted with 200 ml of chloroform. The extract was dried over MgSO₄ and filtered. The filtrate was concentrated until dryness under reduced pressure whereby the end product was obtained in oily form (semi-solid). Yield: 6.1 g (38.3%) The following example illustrate the preparation of the anti-amnestic compositions of the present invention. It is to be construed, however, that the preparation of the anti-amnestic compositions of the present invention is not limited to these examples. Example A Soft capsulated preparations (1) Recipe N-Benzyloxycarbonyl-L-thioprolyl-L-thioprolinal 20 mg Macrogol 400 350 mg Propylene glycol 38 mg Dipotassium glycyrrhizinate 1 mg Menthol oil 1 mg Gelatin 122 mg Glycerol 30.5 mg D-Sorbitol liquid 12.2 mg Ethyl p-hydroxybenzoate 0.8 mg Propyl p-hydroxybenzoate 0.5 mg (2) Preparation N-Benzyloxycarbonyl-L-thioprolyl-L-thioprolinal, Macrogol 400, dipotassium glycyrrhizinate, menthol oil and propylene glycol are homogeneously blended to form a suspension. Separately, a coating agent for soft capsules is manufactured from gelatin, glycerol, D-sorbitol liquid, ethyl p-hydroxybenzoate and propyl p-hydroxybenzoate. Using the suspension and the coating agent, a soft capsule is prepared.

Claims: Thiazolidine derivatives of the general formula I wherein X stands for thioproline residue and R for -CH₂OH or -CHO. N-Benzyloxycarbonyl-L-thioprolyl-L-thioprolinal. A process for the preparation of the thiazolidine derivatives of the general formula I wherein X stands for a thioproline residue and R for -CH₂OH or -CHO, which comprises reacting N-benzyloxycarbonyl-L-thioproline with L-thioprolinol and, optionally, oxidising the resultant N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinol with an oxidizing agent to N-benzyloxycarbonyl-L-thioprolyl-L-thioprolinal. A process according to claim 3, wherein the reaction of N-benzyloxycarbonyl-L-thioproline with L-thioprolinol is carried out in the presence of 1,3-dimethyl-2-chloroimidazolium chloride. An anti-amnestic composition which comprises as an active ingredient thereof at least one thiazolidine derivative according to claim 1 in a pharmacologically active amount together with a conventional excipient. An anti-amnestic composition according to claim 5, wherein the content of the active ingredient is 1-50% by weight based on the weight of the composition. The use of a thiazolidine derivative of the general formula I according to claim 1 for the preparation of an anti-amnestic composition.

Inventors: KADO, KUNIO C/O K.K. YAKULT HONSHA, SHIGA, TOSHIZO C/O K.K. YAKULT HONSHA
Applicants: KABUSHIKI KAISHA YAKULT HONSHA
Application year: 1988
Main classification: C07D417
IPC codes: C07D277, A61K31, A61P25, C07D417